Latest News

Print

New lung cancer treatments lead to vastly improved survival rates

UCLA Health is leading development of therapies that trigger the immune system’s attack on the cancer, along with drugs to stop cancer cell growth

Post Date:November 06, 2020 8:00 AM
Dr. Edward Garon is co-director of the Signal Transduction and Therapeutics research program at UCLA Jonsson Comprehensive Cancer Center

UCLA Health has helped drive monumental advances in the treatment of lung cancer – increasing survival rates in the nation’s leading cause of cancer deaths. The treatments center on immunotherapy to activate the body’s immune system to attack cancer, as well as drugs that target gene mutations fueling tumor growth. Both approaches offer first-line therapies for patients with advanced disease.

“We’ve really had two major revolutions in treatment that have happened in relatively short periods of time,” said Edward Garon, MD, director of the Signal Transduction and Therapeutics Program at the UCLA Jonsson Comprehensive Cancer Center. “This has been a very exciting time where we have started to see new therapies that are able to substantially improve outcomes for patients with lung cancer.”

Click here to read the UCLA Health Connect blog.

Return to full list >>